Biotech · Private company · San Mateo, CA, US

Kronos Bio, Inc.

SEC CIK 0001741830

Track this companyFree. Adds Kronos Bio, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials30 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline6

AnthracyclinePhase 3 · Nucleophosmin 1-mutated Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
CytarabinePhase 3 · Nucleophosmin 1-mutated Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
EntospletinibPhase 3 · Nucleophosmin 1-mutated Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
GilteritinibPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
KB-0742Phase 2 · Relapsed Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
LanraplenibPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)PHASE1_PHASE2 · TERMINATED · started Aug 5, 2022ClinicalTrials.gov NCT05028751 · fetched Nov 12, 2026
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AMLPHASE3 · TERMINATED · started Nov 24, 2021ClinicalTrials.gov NCT05020665 · fetched Nov 12, 2026
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)PHASE1_PHASE2 · TERMINATED · started Feb 8, 2021ClinicalTrials.gov NCT04718675 · fetched Nov 12, 2026